Research
Seaport Therapeutics to present on Thursday, December 11, 2025 at 10:00 AM EST.
Seaport Therapeutics presents at Stifel 2025 Healthcare Conference
Seaport Therapeutics presents at Oppenheimer Private Life Sciences Company Showcase 2025
An oral allopregnanolone prodrug bypasses liver metabolism via lymphatic transport enabling bioavailability in animals and humans
Optimizing Triglyceride Prodrugs of a Model Immunomodulator: Conjugation through the Phenol of Mycophenolic Acid (MPA) Markedly Promotes Lymphatic Drug Transport
Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity
GlyphAllo, a Novel, Orally Bioavailable Prodrug of Allopregnanolone, Induces an EEG Profile Consistent with GABAA Positive Allosteric Modulation in Healthy Volunteers
Predicted Liver Safety of GlyphAgo, a Lymphatic-targeting Prodrug of Agomelatine That Avoids First-pass Metabolism
Frequency of Rater-based Efficacy Assessments Correlated with Magnitude of Placebo Response in Generalized Anxiety Disorder Trials
